Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 40Terminated 16Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 116Carcinoma, Non-Small-Cell Lung 67Multiple Myeloma 56Prostatic Neoplasms 55Lymphoma 40Neoplasm Metastasis 38Leukemia, Lymphocytic, Chronic, B-Cell 35Melanoma 32Leukemia, Myeloid, Acute 32Neoplasms 31Ovarian Neoplasms 30Lymphoma, Non-Hodgkin 27Lung Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Glioblastoma 22Myelodysplastic Syndromes 20Fallopian Tube Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Hodgkin Disease 19Sarcoma 18Carcinoma, Renal Cell 18Squamous Cell Carcinoma of Head and Neck 16Small Cell Lung Carcinoma 16Glioma 16Urinary Bladder Neoplasms 15Colorectal Neoplasms 15Lymphoma, Mantle-Cell 14Leukemia 14Head and Neck Neoplasms 14

Interventions

trametinib 1pembrolizumab 1omipalisib 1lenvatinib 1GSK2141795 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Uveal Melanoma × Clear all
NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Providence Health & Services

Phase 2 Active not recruiting
6 enrolled 11 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡